David S Ettinger

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Thorac Oncol 2:160-5. 2007
  2. doi request reprint Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 28:2598-603. 2010
  3. ncbi request reprint Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
  4. ncbi request reprint An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Semin Oncol 32:S109-10. 2005
  5. ncbi request reprint Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines
    David Ettinger
    Upper Aerodigestive Program, The Sidney Kimmel Comprehensive Cancer Center at John Hopkins School of Medicine, Suite 1100 Harry and Jeanette Weinberg Building, 401 N Broadway, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 3:S17-21. 2005
  6. ncbi request reprint Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21213 1000, USA
    Oncologist 11:358-73. 2006
  7. ncbi request reprint Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Oncologist 7:226-33. 2002
  8. doi request reprint Emerging profile of cetuximab in non-small cell lung cancer
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 New Orleans Street, Baltimore, MD 21231, United States
    Lung Cancer 68:332-7. 2010
  9. ncbi request reprint Multidisciplinary management of lung cancer
    Alexander Spira
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    N Engl J Med 350:379-92. 2004
  10. ncbi request reprint Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come
    Malcolm V Brock
    Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
    J Thorac Cardiovasc Surg 129:64-72. 2005

Detail Information

Publications43

  1. ncbi request reprint Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Thorac Oncol 2:160-5. 2007
    ..Studies to evaluate the drug in US and European patients with extensive stage small cell lung cancer are ongoing. Levels of NQ01 will also be determined in these studies...
  2. doi request reprint Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 28:2598-603. 2010
    ..Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase II study was conducted to confirm safety and activity of amrubicin in the treatment of refractory small-cell lung cancer (SCLC)...
  3. ncbi request reprint Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....
  4. ncbi request reprint An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Semin Oncol 32:S109-10. 2005
    ....
  5. ncbi request reprint Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines
    David Ettinger
    Upper Aerodigestive Program, The Sidney Kimmel Comprehensive Cancer Center at John Hopkins School of Medicine, Suite 1100 Harry and Jeanette Weinberg Building, 401 N Broadway, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 3:S17-21. 2005
  6. ncbi request reprint Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21213 1000, USA
    Oncologist 11:358-73. 2006
    ..Both mAbs and TKIs have demonstrated encouraging results as monotherapies and in combination with chemotherapy and radiotherapy. This review provides a critical update on the status of these novel therapeutics...
  7. ncbi request reprint Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Oncologist 7:226-33. 2002
    ..Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose...
  8. doi request reprint Emerging profile of cetuximab in non-small cell lung cancer
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 New Orleans Street, Baltimore, MD 21231, United States
    Lung Cancer 68:332-7. 2010
    ..Cetuximab does not carry restrictions in use due to safety, and therefore it may be a particularly valuable option for patients who are not eligible for other biologics...
  9. ncbi request reprint Multidisciplinary management of lung cancer
    Alexander Spira
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    N Engl J Med 350:379-92. 2004
  10. ncbi request reprint Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come
    Malcolm V Brock
    Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
    J Thorac Cardiovasc Surg 129:64-72. 2005
    ..Although resection is not the standard of care in treating small cell lung cancer, new platinum drugs and modern staging have allowed the role of surgery to be reevaluated...
  11. ncbi request reprint Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Respirology 12:320-5. 2007
    ..Data are presented to support the standard use of adjuvant therapy in patients with stage II and III disease, as well as data supporting the use of neo-adjuvant therapy in selected patients with non-small cell lung cancer...
  12. ncbi request reprint Chemotherapy for lung cancer: the state of the art in 2009
    Michaela J Higgins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB I, Room 186, Baltimore, MD 21231 1000, USA
    Expert Rev Anticancer Ther 9:1365-78. 2009
    ..Novel targeted systemic therapies and the appropriate selection of treatments for patients based on their tumors' molecular phenotypes and histologies will also be reviewed...
  13. ncbi request reprint Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588)
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room G 88, 1650 Orleans Street, Baltimore, MD, USA
    Lung Cancer 37:311-8. 2002
    ....
  14. ncbi request reprint Managing the patient with borderline resectable lung cancer
    Ani Balmanoukian
    The Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
    Oncology (Williston Park) 24:234-41. 2010
    ..Most importantly, the treatment strategy for stage IIIA/IIIB disease should involve a multimodality approach individualized to the patient's disease stage, age, underlying medical conditions, and performance status...
  15. ncbi request reprint Extensive-stage small-cell lung cancer
    Alexander Spira
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231 1000, USA
    Semin Surg Oncol 21:164-75. 2003
    ..In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment...
  16. doi request reprint Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report
    Patrick M Forde
    Departments of Medical Oncology, Surgery, and Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland and Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland
    J Thorac Oncol 9:414-8. 2014
    ..We report the largest series to date of 49 patients with locally advanced or metastatic pulmonary carcinoid...
  17. ncbi request reprint Non-small cell lung cancer treatment-related bone marrow toxicities
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Semin Oncol 32:S81-5. 2005
    ..In this setting, the use of hematopoietic growth factors may thus be beneficial...
  18. ncbi request reprint Overview and state of the art in the management of lung cancer
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 18:3-9. 2004
    ..Novel innovative therapies, which could include molecular targeting agents, are needed to treat both NSCLC and SCLC...
  19. pmc Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Thorac Oncol 8:619-23. 2013
    ..On the basis of these data, we performed an exploratory clinical study, assessing the efficacy of itraconazole with cytotoxic chemotherapy in the treatment of patients with advanced lung cancer...
  20. doi request reprint Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 New Orleans Street, Baltimore, MD 21231, USA
    Support Care Cancer 17:405-11. 2009
    ..This study investigated physician's attitudes toward the relative importance of chemotherapeutic and antiemetic efficacy in different clinical scenarios...
  21. ncbi request reprint Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer
    Hillary A Hahm
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA
    Clin Cancer Res 8:684-90. 2002
    ..Diethylnorspermine (DENSPM) is one such agent. A focused Phase I clinical trial in patients with advanced non-small cell lung cancer was undertaken...
  22. pmc Targeted therapy for non-small-cell lung cancer: past, present and future
    Patrick M Forde
    Lung Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Expert Rev Anticancer Ther 13:745-58. 2013
    ....
  23. ncbi request reprint The use of chemotherapy in soft-tissue sarcomas
    Alexander I Spira
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Oncologist 7:348-59. 2002
    ..Finally, we discuss the role of chemotherapy in combination with surgery and radiation in the adjuvant and neoadjuvant settings...
  24. ncbi request reprint Non-small cell lung cancer, version 2.2013
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Natl Compr Canc Netw 11:645-53; quiz 653. 2013
    ..The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail...
  25. doi request reprint Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors
    Gang Zheng
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Acta Cytol 57:281-90. 2013
    ..We evaluated CD56 and the quantitative Ki-67 immunohistochemical panel in comparison to synaptophysin and chromogranin, along with cytomorphology to diagnose SCLC...
  26. ncbi request reprint Novel antifolate drugs
    W Thomas Purcell
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G92, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 5:114-25. 2003
    ..Supplementation with folic acid and vitamin B(12) has been shown to reduce the toxicity of pemetrexed without affecting efficacy and has increased the therapeutic index for this novel agent...
  27. ncbi request reprint Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer
    Jin S Lee
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 52:362-70. 2002
    ..We conducted this retrospective cohort study to examine its impact on the outcome of patients undergoing combined chemoradiation therapy for the treatment of locally advanced inoperable non-small-cell lung cancer...
  28. ncbi request reprint Non-small cell lung cancer
    David S Ettinger
    J Natl Compr Canc Netw 6:228-69. 2008
  29. ncbi request reprint Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
    J Clin Oncol 23:3480-7. 2005
    ....
  30. ncbi request reprint NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  31. ncbi request reprint Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer
    Christian Monnerat
    Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 10:5439-46. 2004
    ..It is also known for significant toxicity, which makes it unsuitable for certain patients. Our purpose was to evaluate the efficacy and toxicity of a promising cisplatin-free combination, gemcitabine plus pemetrexed, in NSCLC...
  32. ncbi request reprint Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:342-50. 2005
    ..The purpose of RTOG 97-12 was to determine the maximum tolerated dose (MTD) of thoracic radiation therapy (RT) with concurrent chemotherapy for patients with limited-stage small-cell lung cancer...
  33. ncbi request reprint Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514
    William G Kraybill
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 24:619-25. 2006
    ..On the basis of a positive reported single-institution pilot study, the Radiation Therapy Oncology Group initiated phase II trial 9514 to evaluate its neoadjuvant regimen in a multi-institutional Intergroup setting...
  34. ncbi request reprint Neuroendocrine tumors
    Orlo H Clark
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    J Natl Compr Canc Netw 4:102-38. 2006
  35. ncbi request reprint Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium
    Scott Okuno
    Mayo Clinic College of Medicine, 200 First St, Southwest, Medical Oncology, Rochester, MN 55905, USA
    J Clin Oncol 23:3069-73. 2005
    ..This study was performed to determine the activity of BMS-247550 in patients with soft tissue sarcomas (STSs) who had not received prior chemotherapy for metastatic disease...
  36. ncbi request reprint Soft tissue sarcoma
    George D Demetri
    Dana Faber Brigham and Women s Cancer Center, USA
    J Natl Compr Canc Netw 5:364-99. 2007
  37. ncbi request reprint Non-small cell lung cancer clinical practice guidelines in oncology
    David S Ettinger
    J Natl Compr Canc Netw 4:548-82. 2006
  38. ncbi request reprint Small cell lung cancer clinical practice guidelines in oncology
    Bruce E Johnson
    J Natl Compr Canc Netw 4:602-22. 2006
  39. ncbi request reprint Changing face of small-cell lung cancer: real and artifact
    David S Ettinger
    J Clin Oncol 24:4526-7. 2006
  40. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....
  41. ncbi request reprint Antiemesis
    David S Ettinger
    J Natl Compr Canc Netw 5:12-33. 2007
  42. ncbi request reprint Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial
    Patrick J Loehrer
    Indiana University Medical Center, Indianapolis, IN 46202, USA
    J Clin Oncol 22:293-9. 2004
    ....
  43. ncbi request reprint Small cell lung cancer
    Gregory P Kalemkerian
    J Natl Compr Canc Netw 6:294-314. 2008